Glenn Goddard's most recent trade in Intellia Therapeutics Inc was a trade of 41,316 Stock Option (right to buy) done . Disclosure was reported to the exchange on March 1, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 41,316 | 41,316 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 28,628 | 69,213 (0%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 29.46 per share. | 03 Jan 2024 | 5,365 | 40,585 (0%) | 0% | 29.5 | 158,053 | Common Stock |
| Intellia Therapeutics Inc | Goddard Glenn | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 3,062 | 45,950 (0%) | 0% | - | Common Stock | |
| Intellia Therapeutics Inc | Goddard Glenn | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 3,062 | 3,064 | - | - | Restricted Stock Unit | |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 38,834 | 38,834 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 27,484 | 42,888 (0%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 37.21 per share. | 04 Jan 2023 | 2,427 | 15,404 (0%) | 0% | 37.2 | 90,309 | Common Stock |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 3,062 | 6,126 | - | - | Restricted Stock Unit | |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 3,062 | 17,831 (0%) | 0% | - | Common Stock | |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 12,720 | 14,769 (0%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 12,720 | 12,720 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 3,062 | 9,188 | - | - | Restricted Stock Unit | |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 3,062 | 3,062 (0%) | 0% | - | Common Stock | |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 112.24 per share. | 01 Jan 2022 | 1,013 | 2,049 (0%) | 0% | 112.2 | 113,699 | Common Stock |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Sep 2021 | 3,482 | 12,451 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 180.12 per share. | 07 Sep 2021 | 3,482 | 0 (0%) | 0% | 180.1 | 627,178 | Common Stock |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.58 per share. | 07 Sep 2021 | 3,482 | 3,482 (0%) | 0% | 14.6 | 50,768 | Common Stock |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 160.22 per share. | 30 Aug 2021 | 24,800 | 0 (0%) | 0% | 160.2 | 3,973,456 | Common Stock |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2021 | 22,983 | 41,817 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.27 per share. | 30 Aug 2021 | 22,983 | 22,983 (0%) | 0% | 19.3 | 442,882 | Common Stock |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.27 per share. | 30 Aug 2021 | 5,200 | 5,200 (0%) | 0% | 19.3 | 100,204 | Common Stock |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2021 | 5,200 | 64,800 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2021 | 1,817 | 15,933 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.58 per share. | 30 Aug 2021 | 1,817 | 24,800 (0%) | 0% | 14.6 | 26,492 | Common Stock |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 155.29 per share. | 30 Aug 2021 | 1,700 | 1,696 (0%) | 0% | 155.3 | 263,993 | Common Stock |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 154.29 per share. | 30 Aug 2021 | 1,100 | 3,396 (0%) | 0% | 154.3 | 169,719 | Common Stock |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 153.22 per share. | 30 Aug 2021 | 704 | 4,496 (0%) | 0% | 153.2 | 107,867 | Common Stock |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 157.33 per share. | 30 Aug 2021 | 496 | 900 (0%) | 0% | 157.3 | 78,036 | Common Stock |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 160.84 per share. | 30 Aug 2021 | 300 | 0 (0%) | 0% | 160.8 | 48,252 | Common Stock |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 159.53 per share. | 30 Aug 2021 | 300 | 300 (0%) | 0% | 159.5 | 47,859 | Common Stock |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 158.42 per share. | 30 Aug 2021 | 300 | 600 (0%) | 0% | 158.4 | 47,526 | Common Stock |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 156.10 per share. | 30 Aug 2021 | 300 | 1,396 (0%) | 0% | 156.1 | 46,830 | Common Stock |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2021 | 20,000 | 70,000 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.27 per share. | 05 Aug 2021 | 20,000 | 20,000 (0%) | 0% | 19.3 | 385,400 | Common Stock |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 150.65 per share. | 05 Aug 2021 | 9,902 | 10,098 (0%) | 0% | 150.6 | 1,491,736 | Common Stock |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 151.41 per share. | 05 Aug 2021 | 9,568 | 530 (0%) | 0% | 151.4 | 1,448,691 | Common Stock |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 152.13 per share. | 05 Aug 2021 | 530 | 0 (0%) | 0% | 152.1 | 80,629 | Common Stock |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 73,500 | 73,500 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | Glenn Goddard | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 12,250 | 12,250 | - | - | Restricted Stock Unit |